Efficacy and Safety of Fixed Dose Combination (FDC) of Olopatadine Hydrochloride and Mometasone Furoate Nasal Spray (Molo; Also Referred as GSP 301) in the Treatment of Seasonal Allergic Rhinitis (SAR)

PHASE2CompletedINTERVENTIONAL

Enrollment

180

Participants

Timeline

Start Date

January 27, 2014

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions

Seasonal Allergic Rhinitis

Interventions

DRUG

Molo 1 (also referred as GSP 301-2 NS)

DRUG

Molo 2 (also referred as GSP 301-1 NS)

DRUG

Placebo nasal spray

DRUG

DYMISTA nasal spray

DRUG

PATANASE nasal spray

Trial Locations (1)

Glenmark Investigational Site 1, Mississauga